ArticleJACC. Case reports2025
Arrhythmogenic Right Ventricular Cardiomyopathy Presenting as Monomorphic Ventricular Tachycardia.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionArrhythmogenic right ventricular cardiomyopathy (ARVC) is an autosomal dominant genetic cardiomyopathy characterized by the replacement of right ventricular myocardium with fibrous and adipose tissue, leading to arrhythmias, heart failure, and an increased risk of sudden cardiac death. CASE SUMMARY: A 25-year-old woman without any medical history presented with palpitations after exercise and was found to be in sustained monomorphic ventricular tachycardia. Imaging and presentation met the 2010 modified Task Force Criteria for a diagnosis of ARVC. DISCUSSION: ARVC can be a devastating cause of heart failure and sudden cardiac death in young adults. Once the diagnosis is confirmed, treatment including exercise restriction, antiarrhythmics, goal-directed medical therapy, ablation, and implantable cardioverter-defibrillator placement can lead to marked improvement in prognosis. TAKE-HOME MESSAGE: Clinicians should consider ARVC in young patients presenting with ventricular tachyarrhythmias and use the 2010 modified Task Force Criteria to guide initial diagnosis before confirming with genetic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.